English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe Wake Forest Institute for Regenerative Medicine (WFIRM) will make history this month when the first bioprinted solid tissue constructs soar to the International Space Station (ISS) on board the next all private astronaut mission by commercial space leader Axiom Space.
Tag: WFIRM
Former Senior Level Department of Defense Official Joins RegenMed Hub
The Regenerative Medicine Hub continues to grow and attract top talent with the addition of Ron Hann, PhD, a former senior level official with the Department of Defense.
Immunaeon Joins the RegenMed Hub
Immunaeon is the latest addition to the RegeneratOR’s Innovation AcceleratOR, located in the Regenerative Medicine Hub (RegenMed Hub), a rapidly growing regenerative medicine ecosystem based in the Innovation Quarter of Winston-Salem.
MIMEDX Joins the RegenMed Hub
MIMEDX is the latest addition to the RegeneratOR Innovation Accelerator, located in the Regenerative Medicine Hub (RegenMed Hub), a rapidly growing regenerative medicine ecosystem based in the Innovation Quarter of Winston-Salem.
RTT Medical Joins RegenMed Hub Innovation Accelerator
RTT Medical is the newest tenant of the Innovation Accelerator, a support ecosystem created by the RegenMed Development Organization (ReMDO) to help companies with new or emerging regenerative medicine technologies speed up the translation of products to patients.
WFIRM researchers create specific cancer organoid system to study bacterial effects on immunotherapy
Wake Forest Institute for Regenerative Medicine (WFIRM) researchers are using a tumor organoid system to examine the effects of metabolites secreted by bacteria on a specialized immunotherapy – immune checkpoint blockage, a promising cancer treatment development – to determine why some patients don’t respond or develop a resistance to the treatment over time.
Personalized Immunotherapy Response Studied in Body-on-a-Chip Cancer Models
Wake Forest researchers and clinicians are using patient-specific tumor ‘organoid’ models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer.